skip to content »

Section of Atherosclerosis

Houston, Texas

BCM faculty, staff and trainees are the heart of the organization.
Section of Atherosclerosis and Vascular Medicine
not shown on screen

Publications 2006

  1. Vasudevan AR, Wu H, Xydakis AM, Jones PH, Smith EO, Sweeney JF, Corry DB, Ballantyne CM. Eotaxin and obesity. J Clin Endocrinol Metab. 2006;91:256-261.

  2. Barter PJ, Ballantyne CM, Carmena R, Cabezas MC, Chapman MJ, Couture P, Graaf J, Durrington PN, Faergeman O, Frohlich J, Furberg CD, Gagne C, Haffner SM, Humphries SE, Jungner I, Krauss RM, Kwiterovich P, Marcovina S, Packard CJ, Pearson TA, Reddy KS, Rosenson R, Sarrafzadegan N, Sniderman AD, Stalenhoef AF, Stein E, Talmud PJ, Tonkin AM, Walldius G, Williams KM. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 2006;259:247-258.
  3. Nambi V, Ballantyne CM. C-reactive protein and non-statin lipid-lowering therapy. In: Ridker PM, Rifai N (eds). C-reactive protein and cardiovascular disease. St-Laurent, Quebec: MediEdition 2006:247–262.
  4. Volcik KA, Ballantyne CM, Coresh J, Folsom AR, Wu KK, Boerwinkle E. P-selectin Thr715Pro polymorphism predicts P-selectin levels but not risk of incident coronary heart disease or ischemic stroke in a cohort of 14595 participants: The Atherosclerosis Risk In Communities Study. Atherosclerosis 2006;186:74-79.
  5. Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, Boerwinkle E, Mosley TH Jr, Sorlie P, Diao G, Sharrett AR. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the Atherosclerosis Risk in Communities study. Arch Intern Med 2006;166:1368-1373.
  6. Rifai N, Ballantyne CM, Cushman M, Levy D, Myers GL. Point: High-sensitivity C-reactive protein and cardiac C-reactive protein assays: is there a need to differentiate? Clin Chem 2006;52:1254-1256.
  7. Volcik KA, Barkley RA, Hutchinson RG, Mosley TH, Heiss G, Sharrett AR, Ballantyne CM, Boerwinkle E. Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. Am J Epidemiol 2006;164:342-348.
  8. Nambi V, Ballantyne CM. Lipoprotein-associated phospholipase A2: pathogenic mechanisms and clinical utility for predicting cardiovascular events. Curr Atheroscler Rep 2006;8:374-381.
  9. Schmidt MI, Duncan BB, Vigo A, Pankow JS, Couper D, Ballantyne CM, Hoogeveen RC, Heiss G, for the ARIC Investigators. Leptin and incident type 2 diabetes: risk or protection? Diabetologia 2006;49:2086-2096.
  10. Yang CY, Chen HH, Huang MT, Raya JL, Yang JH, Chen CH, Gaubatz JW, Pownall HJ, Taylor AA, Ballantyne CM, Jenniskens FA, Smith CV. Pro-apoptotic low-density lipoprotein subfractions in type II diabetes. Atherosclerosis 2006; [Epub ahead of print]
  11. Abe Y, Fornage M, Yang CY, Bui-Thanh NA, Wise V, Chen HH, Rangaraj G, Ballantyne CM. L5, the most electronegative subfraction of plasma LDL, induces endothelial vascular cell adhesion molecule 1 and CXC chemokines, which mediate mononuclear leukocyte adhesion. Atherosclerosis 2006; [Epub ahead of print]
  12. Nettleton JA, Steffen LM, Ballantyne CM, Boerwinkle E, Folsom AR. Associations between HDL-cholesterol and polymorphisms in hepatic lipase and lipoprotein lipase genes are modified by dietary fat intake in African American and White adults. Atherosclerosis 2006; [Epub ahead of print]
  13. Hoogeveen RC, Ballantyne CM, Bang H, Heiss G, Duncan BB, Folsom AR, Pankow JS. Circulating oxidised low-density lipoprotein and intercellular adhesion molecule-1 and risk of type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Diabetologia 2007;50:36-42.
  14. Gaubatz JW, Gillard BK, Massey JB, Hoogeveen RC, Huang M, Lloyd EE, Raya JL, Yang CY, Pownall HJ. Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A2. J Lipid Res 2007;48:348-357.
  15. Schmidt MI, Duncan BB, Vigo A, Pankow JS, Couper D, Ballantyne CM, Hoogeveen RC, Heiss G, for the ARIC Investigators. Response to comment on: Schmidt MI, Duncan BB, Vigo A et al. Leptin and incident type 2 diabetes: risk or protection? Diabetologia 2007;50:237-238.

E-mail this page to a friend